The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.

The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

The present invention provides the use of neuregulin protein for the preparation of medication for preventing, treating or delaying heart failure in humans and methods for preventing, treating or delaying heart failure in humans using said medication.

The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-I) fused to a HER3 monoclonal antibody (mAb) backbone and to a method of treating atrial fibrillation and/or cardiac fibrosis in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.

The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.

The invention is a method for treating a heart disease, in particular acute myocardial infarction (AMI) in a subject comprising the step of administering to the subject a Tjp1 inhibitor, wherein administration of said Tjp1 inhibitor promotes cardiomyocyte proliferation. The invention further includes use of Tjp1 inhibitor in the manufacture of a medicament for a heart disease, a patch, and a nucleic acid encoding a Tjp1 inhibitor. In a particular embodiment, the Tjp1 inhibitor is a nucleic acid, i.e. an siRNA or shRNA of Tjp1. The invention also includes administration of said Tjp1 inhibitor in combination with Neuregulin-1 (NRG1), Fibroblast growth factor (FGF), Vascular endothelial growth factor (VEGF) or Follistatin-like 1 (Fst1) and wherein said inhibitor is delivered in an adeno-associated virus of serotype 9 (AAV 9).

Provided herein are methods of treating congenital heart disease in a patient, such as tetralogy of Fallot, with beta blockers to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient. Also provided herein are uses for beta blockers for treating congenital heart disease, such as tetralogy of Fallot, in a patient to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient.

Provided herein are methods of treating congenital heart disease in a patient, such as tetralogy of Fallot, with beta blockers to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient. Also provided herein are uses for beta blockers for treating congenital heart disease, such as tetralogy of Fallot, in a patient to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient.

The present application describes a method of regenerating nerve, which steps include generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter; transfecting in vitro a population of cultured cells with the recombinant vector, resulting in a population of the cultured cells; and transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes regeneration of the nerve.

The present application describes a method of regenerating nerve, which steps include generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter; transfecting in vitro a population of cultured cells with the recombinant vector, resulting in a population of the cultured cells; and transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes regeneration of the nerve.